FDA issues Actemra drug for COVID under Emergency Use Authorization (EUA)

The drug, Actemra (tocilizumab) has shown efficacy in treating COVID patients with better results by reducing the death and mortality rate along with complications. FDA has issued an Emergency Use Authorization (EUA) for the Actemra (tocilizumab) in COVID 19 patients.

With new strains of COVID hitting the world, the FDA has started issuing Emergency Use Authorization (EUA) for COVID patients. Those suffering from COVID can now get a sigh of relief with this Emergency Use Authorization (EUA) by FDA. This year, the COVID vaccination drives have started. The good news is that there are less fewer of COVID cases occurring this month which has shown a drastic drop in the number of COVID infected cases. This is worth mentioning as the COVID vaccines are making a positive wave of action for many people around the globe. 

The World Health Organization is constantly monitoring the number of COVID-infected patients around the globe. The pandemic has brought everything to a standstill. However, this month of June 2021 is definitely bringing about a positive movement in terms of the health and economic development of the nation. 

Prediction about the third wave of the COVID

A few months ago, COVID had disrupted our Indian community and created great havoc which was impossible to deal with. The second wave of pandemics in India was an emergency stage around the globe. It was required for us to be future-ready and deal with situations. People around the globe have been talking about the third wave of COVID which is suggested to hit the world in October 2021. We need to stay alert on this and protect people from falling prey to COVID. 

Vaccination drives can help: Following basic COVID protocols is very important 

With vaccination drives across the world, many people are being protected from the infection of COVID. It is important to note that even after the vaccination, we have to follow certain COVID protocols strictly to keep the third wave of COVID at bay.  

These few months of the second wave of COVID have been very challenging. With the lockdown and gradual unlocking situation of India, the situation seems to come back on track and normalcy. We can just hope for the best for a better future and healthy life. Th eCOVID 19 has provided a long-standing and sustainable evidence-based situation to deal with. 

Actemra (tocilizumab) can be used for COVID 19 has proven to have good efficacy 

FDA is issued Emergency Use Authorization (EUA) for the drug Actemra (tocilizumab) for the treatment of hospitalized patients including senior citizens, adults, and the pediatric population ( up to 2 years of age). It is important to provide a drug of treatment for COVID which can help patients to fall prey to the complications of COVID. The efficacy of the drug has been checked through clinical trials of hospitalized COVID patients. The drug Actemra (tocilizumab) can be given in addition to the routine care of patients receiving COVID 19 treatment which include systemic corticosteroids. This has shown to reduce the risk of death through a 28- day follow-up and decrease the hospitalization time for COVID infected patients. It was noted that the risk of patients being placed on ventilators or death through 28 - day follow up was also decreased. This ensures that the medicine (tocilizumab) is effective and safe and can be used for COVID 19 patients for better results 





Tags : #FDA #FDAapproval #EmergencyUseAuthorization #Actemra #medicircle #myhealth

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024
Embark on a Creative Journey: "Kala For A Cause" Unveils Pottery Workshop Series March 26, 2024
Healthtech pioneer Aurora Innovation appoints new CEO – expands in Europe with service that streamlines patient-healthcare interactionMarch 26, 2024
In A Rare Feat, 45 YO Woman Walks Within 6 Hrs. Of Dual Robotic Surgery In A Single Operation At HCGMCCMarch 26, 2024
Improve Cancer Care through Automated CT Analysis: Oncoshield – CTMarch 26, 2024